Literature DB >> 28413128

Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

Tom Powles1, Kate Smith2, Arnulf Stenzl3, Jens Bedke4.   

Abstract

Immune checkpoint inhibitors are a new treatment option in metastatic urothelial cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are needed. These should go beyond PD-L1 expression, which is showing inconsistent results across trials.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28413128     DOI： 10.1016/j.eururo.2017.03.047

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  9 in total

Review 1.  Is There a Role for Immunotherapy in Prostate Cancer?

Authors:  Alessandro Rizzo; Veronica Mollica; Alessia Cimadamore; Matteo Santoni; Marina Scarpelli; Francesca Giunchi; Liang Cheng; Antonio Lopez-Beltran; Michelangelo Fiorentino; Rodolfo Montironi; Francesco Massari
Journal:  Cells       Date:  2020-09-08       Impact factor: 6.600

Review 2.  The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis.

Authors:  Alessandro Rizzo; Matteo Santoni; Veronica Mollica; Angela Dalia Ricci; Concetta Calabrò; Antonio Cusmai; Gennaro Gadaleta-Caldarola; Gennaro Palmiotti; Francesco Massari
Journal:  J Pers Med       Date:  2022-05-20

Review 3.  [Mode of action, new targets and potential biomarkers in modern immunotherapy].

Authors:  J Bedke; V Stühler; T Todenhöfer; A Stenzl
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

4.  Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Authors:  Andrea Necchi; Gregory R Pond; Sumanta K Pal; Neeraj Agarwal; Daniel W Bowles; Elizabeth R Plimack; Evan Y Yu; Sylvain Ladoire; Jack Baniel; Simon Crabb; Gunter Niegisch; Sandy Srinivas; Dominik R Berthold; Jonathan E Rosenberg; Thomas Powles; Aristotelis Bamias; Lauren C Harshman; Joaquim Bellmunt; Matthew D Galsky
Journal:  Clin Genitourin Cancer       Date:  2017-11-01       Impact factor: 2.872

Review 5.  Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.

Authors:  Vadim S Koshkin; Petros Grivas
Journal:  Curr Oncol Rep       Date:  2018-04-11       Impact factor: 5.075

6.  CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.

Authors:  Feng Gao; Jing Chen; Jia Wang; Peixiang Li; Sheng Wu; Jue Wang; Yong Ji
Journal:  Biochem Biophys Rep       Date:  2019-10-03

Review 7.  Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years.

Authors:  Andreas Koulouris; Christos Tsagkaris; Michail Nikolaou
Journal:  Toxins (Basel)       Date:  2021-02-15       Impact factor: 4.546

Review 8.  Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis.

Authors:  Alessandro Rizzo; Veronica Mollica; Matteo Santoni; Gennaro Palmiotti; Francesco Massari
Journal:  J Clin Med       Date:  2022-02-17       Impact factor: 4.241

9.  Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.

Authors:  Elodie Dang; Alexandre Vallée; Coralie Lepage-Seydoux; Karine Sejean; Brigitte Bonan; Christine Abraham; Philippe Beuzeboc; Raffaele Ratta
Journal:  Curr Oncol       Date:  2022-02-10       Impact factor: 3.677
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.